MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients
- 1 July 2003
- journal article
- Published by Wolters Kluwer Health in AIDS
- Vol. 17 (11), 1696-1698
- https://doi.org/10.1097/00002030-200307250-00016
Abstract
P-glycoprotein, a membrane-localized protein transporter, codified by the MDR1 gene, influences the response to pharmacological treatments, including antiretroviral drugs. MDR1 polymorphism C3435T is correlated with the functionality of the protein. We investigated the influence of this polymorphism in the reconstitution of the peripheral CD4 T cell pool in 149 drug-naive HIV-positive patients starting highly active antiretroviral therapy. The MDR1 C3435Tpolymorphism did not influence response to therapy, suggesting no disadvantages for individuals with a different genotype.Keywords
This publication has 7 references indexed in Scilit:
- Features of ‘CD4-exploders', HIV-positive patients with an optimal immune reconstitution after potent antiretroviral therapyAIDS, 2002
- Genetic polymorphisms of Fas (CD95) and FasL (CD178) in human longevity: studies on centenariansCell Death & Differentiation, 2002
- Functional Polymorphisms of the Human Multidrug Resistance ( MDR1 ) Gene: Correlation with P glycoprotein Expression and Activity in vivoPublished by Wiley ,2002
- Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics studyThe Lancet, 2002
- Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivoProceedings of the National Academy of Sciences, 2000
- P-Glycoproteins and Multidrug ResistanceAnnual Review of Pharmacology and Toxicology, 1996
- Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes [see comments]Blood, 1992